Razoxane structure
|
Common Name | Razoxane | ||
|---|---|---|---|---|
| CAS Number | 21416-67-1 | Molecular Weight | 268.26900 | |
| Density | 1.333g/cm3 | Boiling Point | 531.5ºC at 760mmHg | |
| Molecular Formula | C11H16N4O4 | Melting Point | 193ºC | |
| MSDS | USA | Flash Point | 275.3ºC | |
Use of RazoxaneRazoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1]. |
| Name | 4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione) |
|---|---|
| Synonym | More Synonyms |
| Description | Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1]. |
|---|---|
| Related Catalog | |
| Target |
Topoisomerase II |
| In Vitro | Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model. |
| In Vivo | Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2]. Animal Model: Sprague-Dawley rats[2] Dosage: 30 mg/kg or 10 mg/kg per day Administration: Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation Result: Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. |
| References |
| Density | 1.333g/cm3 |
|---|---|
| Boiling Point | 531.5ºC at 760mmHg |
| Melting Point | 193ºC |
| Molecular Formula | C11H16N4O4 |
| Molecular Weight | 268.26900 |
| Flash Point | 275.3ºC |
| Exact Mass | 268.11700 |
| PSA | 98.82000 |
| Vapour Pressure | 1.33E-13mmHg at 25°C |
| Index of Refraction | 1.534 |
| Storage condition | room temp |
| Water Solubility | DMSO: soluble40mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| RIDADR | NONH for all modes of transport |
|---|---|
| RTECS | TL6389900 |
|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
J. Med. Chem. 51 , 6740-51, (2008) The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared ... |
|
|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicol. Mech. Methods 18 , 217-27, (2008) ABSTRACT Drug-induced phospholipidosis (PL) is a condition characterized by the accumulation of phospholipids and drug in lysosomes, and is found in a variety of tissue types. PL is frequently manifes... |
|
|
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
J. Clin. Oncol. 30(10) , 1042-9, (2012) Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identify... |
| 4,4'-propylenebis(piperazine-2,6-dione) |
| 4,4'-Propane-1,2-diyldipiperazine-2,6-dione |
| 4,4'-(1-Methylethylene)bis(2,6-piperazinedione) |
| dl-1,2-bis(3,5-dioxopiperazin-1-yl)-propane |
| Propyliminum |
| RAZOXANUM |
| 1,2-bis(3,5-dioxopiperazin-1-yl)-propane |
| (+)-1,2-bis(3,5-dioxopiperazinyl)propane |
| (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane |
| Razoxane |